Impella, which J&J touts as the world’s smallest heart pump, has a range of devices used for various heart conditions. Lexeo ...
WASHINGTON, D.C.—Johnson & Johnson MedTech’s Abiomed announced that its compressible, expandable heart pump has cleared a pivotal trial, and it’s now headed for FDA review in the coming months. The ...
Abiomed, part of Johnson & Johnson MedTech, has identified an issue that may affect the detection of its Impella pumps when connected to their controllers, according to an alert put out by the US Food ...
Certain Automated Impella Controllers (AICs), the main control interface for the Impella catheter (Abiomed/Johnson & Johnson MedTech), should not be used after another issue potentially affecting pump ...
Last week, the FDA announced it was aware that Abiomed had sent a letter to affected customers recommending updated instructions for use for all Automated Impella Controllers (AIC). Abiomed identified ...
DANVERS, Mass. – October 24, 2024 – Novel data on the benefits of Impella ® heart pump technology in high-risk percutaneous coronary intervention (PCI) and cardiogenic shock will be presented during ...
Abiomed, part of Johnson & Johnson MedTech, recently presented positive results from the first completed pivotal trial on Impella ECP, a novel transvalvular axial flow pump with compressible pump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback